2Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology, 2006,66:1654-1660.
3Zona C, Niespodziany I, Marchettic M, et al. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca^2+ currents. Seizures, 2001, 10: 279-286.
4Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA and glycine-gated currents. Br J Pharmacol,2002,136:659-672.
5Lynch BA,Lambeng N,Nocka K, et al,The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA,2004,101:9861-9866.
6Growder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA, 1999,96 : 15268-15273.
7Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res,2003,53 : 57-64.
8Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double blind, responder selected study evaluating monotherapy European Levetiracetam Study Group. Epilepsia, 2000,41 : 1276-1253.
9Welty TE, Gidal BE, Ficker DM, et al. Levetiracetam : a different approach to the phannacotherapy of epilepsy. Ann Phannacother, 2002,36: 296-304.
